Different studies have demonstrated the relevance of antagonists of CHRM3 as a possible treatment in tumoral proliferation [70,71]; in particular, studies in gastric cancer cells have shown increasing concentrations of CHRM3 antagonists like 4-DAMP and darifenacin in a model of tumor xenograft growth in nude mice [72]. Here, CHRM3 is linked to neoplasm.